Skip to main content

Table 2 Comparison of cumulative dose of anticancer drug (mg/body)

From: Long-term exposure to pemetrexed induces chronic renal dysfunction in patients with advanced and recurrent non-squamous cell lung cancer: a retrospective study

  r+0.4<, N = 49 r+0.4, N = 41 P a)
CBDCA 3200 (2410, 3,877) 2500 (2000, 3,360) 0.10
PEM 9100 (6365, 11,260) 5600 (4140, 7,440) < 0.01
BEV 8250 (4790, 12,000) 5510 (4020, 7,865) 0.07
  1. Median (interquartile range)
  2. CBDCA carboplatin, PEM pemetrexed, BEV bevacizumab
  3. a)Mann-Whitney U test